- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
--Appointment Expands Leadership Team and Strengthens Commercial Focus--
BioNanomatrix, Inc., a developer of breakthrough nanoscale platforms for molecular diagnostics, personalized medicine and biomedical research, today announced the appointment of Gary Zweiger, Ph.D., as vice president of business development. Dr. Zweiger has over a decade of strategic business development experience with leading biotechnology and genomics companies. He will focus on expanding BioNanomatrix's commercial and research partnerships for its breakthrough nanoscale whole genome technology platform in multiple markets, including research, diagnostics and personalized medicine.
"Gary's background and experience are close to ideal for our newly created senior business development position, and we are very pleased to have him on board," said Dr. Michael Boyce-Jacino, chief executive officer of BioNanomatrix. "Gary's scientific expertise is directly relevant to our end-user markets and his extensive business development and alliance management experience should be invaluable as we expand our network of collaborations and commercial partnerships."
BioNanomatrix is applying its expertise in nanochips, nanodevices and nanosystems to develop its platform technology providing fast, comprehensive and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Among its current development efforts is a federally funded project in partnership with Complete Genomics Inc. for very low-cost sequencing of the human genome.
"This is an exciting time to join BioNanomatrix as the company is advancing a potentially transformative single-molecule, whole genome sorting and imaging technology that will enable scientists to analyze clinically relevant DNA sequence variation, copy number and positional information, and to do so much faster, more cost-effectively and with far better resolution than existing methods," said Dr. Zweiger. "There are many possible applications for our technology, and I look forward to working with the BioNanomatrix team to expand the company's growing list of partnerships and help establish new opportunities for growth."
Prior to joining BioNanomatrix, Dr. Zweiger was senior director of business development at Affymetrix, where he managed collaborations, developed new business opportunities and secured revenue-generating research partnerships. Previously, he was director of business development for Applied Biosystems' Cell and Molecular Biology division, where he managed collaborations and business development activities for the company's PCR, DNA sequencing, RNA interference and cell biology businesses. Prior to Applied Biosystems, Dr. Zweiger was at Agilent Technologies, where he held positions of increasing responsibility, directing efforts to identify, assess and secure new business opportunities. Earlier in his career, Dr. Zweiger served as a strategic advisor and consultant to biotechnology and genomics companies and to the financial community. He has published a general audience book on sequencing the human genome, authored numerous scientific publications and holds seven patents. Dr. Zweiger received a Ph.D. in genetics and a B.S. in biological sciences from Stanford University and completed a post-doctoral fellowship in molecular oncology at Genentech Inc.
About BioNanomatrix, Inc.
BioNanomatrix isdeveloping breakthrough nanoscale whole genome imaging and analytic platforms for applications in genetic diagnostics, personalized medicine and biomedical research. The company is applying its expertise in nanochips, nanodevices and nanosystems to develop its patented platform technology to provide fast, comprehensive, and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Its current development efforts include a federally funded project to sequence the human genome at a cost of $100. BioNanomatrix's technologies are licensed exclusively from Princeton University. Founded in 2003, the company is headquartered in Philadelphia, Pennsylvania.
For more information, please click here
GendeLLindheim BioCom Partners
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016